Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.45 |
| ▸ | CCND1 | P24385 | 7/20 | 0.45 |
| ▸ | CCND2 | P30279 | 6/20 | 0.45 |
| ▸ | CCND3 | P30281 | 6/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | USP2 | O75604 | 7/20 | 0.41 |
| ▸ | CASP1 | P29466 | 7/20 | 0.41 |
| ▸ | CASP7 | P55210 | 7/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | HBB | P68871 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753641 | 0.83 | CYP1A2 (0.41) | CDK4CCND1CCND2CCND3EGFR | |
| SCHEMBL5750776 | 0.78 | CDK4 (0.58) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL29507500 | 0.68 | CDK4 (0.63) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL4830672 | 0.68 | CDK4 (0.63) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL2006201 | 0.68 | PIK3CA (0.50) | FGFR1 | |
| SCHEMBL5114082 | 0.68 | WEE1 (0.60) | CDK4CCND1CCND2CCND3EGFR | |
| SCHEMBL13553978 | 0.67 | PLK2 (0.60) | CDK4CCND1CCND2CCND3EGFR | |
| SCHEMBL13554032 | 0.67 | CDK4 (0.70) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL4828507 | 0.67 | CDK4 (0.65) | CDK4CCND1CCND2CCND3FGFR1 | |
| SCHEMBL29507395 | 0.67 | CDK4 (0.65) | CDK4CCND1CCND2CCND3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | claimed |
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | CDK2, CDK4, CDK1 | CDK4 2/4885CCND1 18/4885CCND2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.